Issues: While existing policies are relatively unified at the macro level, their implementation across various administrative levels exacerbates disparities
A., Thal, L
Keep an eye on your zinc levels
Current FDA labels document these patterns in detail: Wegovy (semaglutide) lists nausea (44% vs 16% placebo), vomiting (25% vs 6%), diarrhea (30% vs 16%), constipation (24% vs 11%), abdominal distension and eructation, with severe GI events in 4.1% versus 0.9% placebo.[2] Zepbound (tirzepatide) lists nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, eructation, and gastroesophageal reflux disease among common adverse reactions, with severe GI disease as a Warnings and Precautions item.[3] Both labels include postmarketing reports of ileus, severe constipation including fecal impaction, and acute kidney injury related to dehydration from severe GI symptoms
Do I need a Yakkan Shmei for Mounjaro or Zepbound
The Mounjaro Savings Card is a copay assistance program offered by Eli Lilly that helps reduce the cost of medication for people with commercial or private insurance
